

Resource Summary Report

Generated by [NIF](#) on Aug 22, 2026

SynergyFinder web application

RRID:SCR_026127

Type: Tool

Proper Citation

SynergyFinder web application (RRID:SCR_026127)

Resource Information

URL: <https://synergyfinder.fimm.fi/synergy/20241204032047220526/>

Proper Citation: SynergyFinder web application (RRID:SCR_026127)

Description: Stand-alone web-application for interactive analysis and visualization of multi-drug (2 or more drugs) multi-dose combination response data., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Resource Type: software resource, web application

Keywords: interactive analysis, visualization, multi-drug, multi-dose, combination response data,

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: SynergyFinder web application

Resource ID: SCR_026127

Record Creation Time: 20241205T053247+0000

Record Last Update: 20260821T194322+0000

Ratings and Alerts

No rating or validation information has been found for SynergyFinder web application.

No alerts have been found for SynergyFinder web application.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Malik S, et al. (2026) Functional characterization of Candida auris DHA1 transporters conferring flucytosine resistance. *Frontiers in microbiology*, 17, 1806653.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). *EMBO molecular medicine*, 18(5), 1933.

Foster M, et al. (2026) A Personalized Therapeutic Approach for Liver Cancers Expressing the African-Centric P47S Variant of TP53. *Molecular cancer research : MCR*, 24(7), 618.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. *iScience*, 29(6), 116184.

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 596.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. *Cell reports*, 45(1), 116784.

Patel UA, et al. (2026) CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer. *Molecular cancer therapeutics*, 25(1), 183.

Hoang TS, et al. (2026) Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs. *Cancer prevention research (Philadelphia, Pa.)*, 19(2), 79.

Chen Y, et al. (2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. *Cancer research*, 85(14), 2753.

Giuntini F, et al. (2025) MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. *Cell reports*, 44(12), 116604.

Totiger TM, et al. (2025) XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance. *Cancer research*, 85(17), 3219.